Rapid high-performance liquid chromatographic method for determination of adefovir in plasma using UV detection: application to pharmacokinetic studies

Abstract

A rapid, sensitive and reproducible HPLC method was developed and validated for the analysis of adefovir (CAS 106941-25-7) in human plasma. The separation was achieved on a monolithic silica column (Chromolith Performance RP-18e, 10064.6 mm) using acetonitrile-ammoniumdihydrogen phosphate buffer (6: 94, v/v), pH 5.2, as the mobile phase at a flow rate of 1.5 ml min–1. The wavelength was set at 260 nm. The assay enables the measurement of adefovir for therapeutic drug monitoring with a minimum quantification limit of 1 ng ml–1. The method involves a simple protein precipitation procedure. Analytical recovery was complete. The calibration curve was linear over the concentration range 1–40 ng ml–1. The coefficients of variation for inter-day and intra-day assay were found to be less than 5%. The method was applied to the determination of adefovir in plasma from 12 subjects dosed with adefovir 2610 mg tablets and pharmacokinetic parameters were evaluated.

Key words

Adefovir - HPLC - Nucleotide analog reverse transcriptase inhibitor - Pharmacokinetic studies - Plasma concentration

• References

• 1 Qaqish R, Mattes K, Ritchie D.. Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. Clin Ther. 2009; 25: 3084-99
• 2 Danta M, Dusheiko G.. Adefovir dipivoxil: review of a novel acyclic nucleoside analogue. IntJ Clin Pract. 2004; 58: 877-86
• 3 Hughes W, Shenep J, Rodman J, Fridland A, Willoughby R, Blanchard S et al Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000; 44: 1041-6
• 4 Sparidans R, Veldkamp A, Hoetelman M, Beijnen J.. Improved and simplified liquid chromatographic assay for adefovir, a novel antiviral drug, in human plasma using derivatization with chloroacetaldehyde. J Chromatogr B. 1999; 736: 115-21
• 5 Cundy K, Barditch-Crovo P, Walker R, Collier A, Ebeling D, Toole J et al Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 1995; 39: 2401-5
• 6 Naesens L, Balzarini J, De Clercq E.. Acyclic adenine nucleoside phosphonates in plasma determined by high-performance liquid chromatography with fluorescence detection. Clin Chem. 1992; 38: 480-5
• 7 Zhao L, Chen Y, Zhang Y, Yang H, Zhong D.. [Determination of adefovir in monkey plasma by liquid chromatography-tandem mass spectrometry]. Yao Xue Xue Ba. 2003; 38: 120-3 Chinese
• 8 Liu Y, Xu G, Xu C, Garcia L, Lin C, Yeh L.. Ultra sensitive method for the determination of 9-(2-phosphonylmethoxy-ethyl)adenine in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B. 2004; 803: 293-8
• 9 Chen X, Liu D, Zhu L, Zhong D.. Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of adefovir in human plasma. Rapid Commun Mass Spectrom. 2005; 19: 1893-8
• 10 Bi H, Zhong G, Zhuo S, Chen X, Huang M.. Determination of adefovir in human plasma by liquid chromatography/ tandem mass spectrometry: application to a pharmacokinetic study. Rapid Commun Mass Specfrom. 2005; 19: 2911-7
• 11 Sun D, Wang H, Wang B, Guo R.. Development and validation of a sensitive LC-MS/MS method for the determination of adefovir in human serum and urine. J Pharm BiomedAnal. 2006; 42: 372-8
• 12 Xiong Z, Zhang Y, Qin F, Qin T, Yang S, Li F.. Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of adefovir in human plasma and its application to a pharmacokinetic study. J ChromaSStogr B. 2010; 878: 2111-6